Background Trials of endovascular therapy for ischemic stroke have produced variable
results. We conducted this study to test whether more advanced imaging selection, recently …

Background Thrombolysis for acute ischaemic stroke has been investigated in several
clinical trials, with variable results. We have assessed the safety and efficacy of intravenous …

Background In 2015, five randomised trials showed efficacy of endovascular thrombectomy
over standard medical care in patients with acute ischaemic stroke caused by occlusion of …

Objective Preclinical evaluation of neuroprotectants fostered high expectations of clinical
efficacy. When not matched, the question arises whether experiments are poor indicators of …

Objectives. —To determine whether the administration of 1.5 million units of streptokinase
intravenously within 4 hours of the onset of acute ischemic stroke would reduce morbidity and …

Background Intravenous alteplase is the only approved treatment for acute ischemic stroke.
Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an …

Background Early administration of intravenous recombinant tissue plasminogen activator (rt-PA)
after ischaemic stroke improves outcome. Previous analysis of combined data from …

Background Alteplase is effective for treatment of acute ischaemic stroke but debate continues
about its use after longer times since stroke onset, in older patients, and among patients …

Importance Endovascular thrombectomy with second-generation devices is beneficial for
patients with ischemic stroke due to intracranial large-vessel occlusions. Delineation of the …

Stroke is the second highest cause of death globally and a leading cause of disability, with
an increasing incidence in developing countries. Ischaemic stroke caused by arterial …